Anixa Biosciences Inc (NASDAQ:ANIX) Receives Average Rating of “Hold” from Brokerages

Anixa Biosciences Inc (NASDAQ:ANIX) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.50.

Several equities analysts have recently commented on the company. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 30th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Weiss Ratings raised shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. Finally, Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th.

Insider Buying and Selling

In other news, CEO Amit Kumar bought 21,000 shares of Anixa Biosciences stock in a transaction on Friday, June 12th. The shares were bought at an average price of $2.50 per share, with a total value of $52,500.00. Following the acquisition, the chief executive officer directly owned 630,812 shares in the company, valued at approximately $1,577,030. This represents a 3.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders purchased 50,024 shares of company stock worth $148,971. Company insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently added to or reduced their stakes in ANIX. AXQ Capital LP bought a new position in shares of Anixa Biosciences in the 2nd quarter worth about $41,000. Corient Private Wealth LP bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $105,000. Canada Pension Plan Investment Board bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $38,000. Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $29,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Anixa Biosciences during the second quarter worth about $29,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Price Performance

NASDAQ:ANIX opened at $3.66 on Wednesday. The firm has a 50-day moving average of $3.26 and a two-hundred day moving average of $2.96. The stock has a market cap of $124.51 million, a P/E ratio of -11.81 and a beta of 0.55. Anixa Biosciences has a 1-year low of $2.32 and a 1-year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. As a group, equities analysts expect that Anixa Biosciences will post -0.31 earnings per share for the current year.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.